Pegaspargase (Oncaspar®) powder for solution for injection/infusion is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||05 February 2020|
|Rapid Review completed||13 March 2020|
|Rapid Review Outcome||A full HTA is not recommended. The NCPE recommends that pegaspargase (Oncaspar®) be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement, March 2020